Novo Nordisk

News

Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.

News

Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.

News

Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.

News

Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.

News

Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

Patients

Deep Dive editor Eloise McLennan reports on Novo Nordisk's inaugural Weight Talks Summit in London.